We believe that patients should have access to innovative medicines.
Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.
This paper provides a high-level explanation of the financial flows that occur as brand medicines move through the supply chain for retail, mail-order and specialty drugs.
